Overview

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions